Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations

Dow Jones

10/17

By Josh Beckerman

Sensei Biotherapeutics shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company.

Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year.

The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors.

On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 16, 2025 15:32 ET (19:32 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576720659"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576720659\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576720659?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 03:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576720659","market":"sg","top_or_hot":-1,"title":"Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company. \n</p>\n<p>\n  Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year. \n</p>\n<p>\n  The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors. \n</p>\n<p>\n  On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 16, 2025 15:32 ET (19:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-17 03:32</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company. \n</p>\n<p>\n  Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year. \n</p>\n<p>\n  The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors. \n</p>\n<p>\n  On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 16, 2025 15:32 ET (19:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576720659","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576720659","pubTimestamp":1760643120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sensei Biotherapeutics shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company.Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year.The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors.On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNSE":"Sensei Biotherapeutics, Inc."},"translate_title":"Sensei Biotherapeutics股价在预定演示前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNSE":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nSensei Biotherapeutics shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company. \n\n\n  Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year. \n\n\n  The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors. \n\n\n  On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2025 15:32 ET (19:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}